{"entity":{"id":"ionetix","kind":"company","name":"IONETIX","aka":["Ionetix Corporation"],"tldr":"A Michigan company that builds compact superconducting particle accelerators and uses them to make radioactive materials for both diagnostic scans and cancer therapies, including two rare isotopes, actinium-225 and astatine-211.","summary":"IONETIX Corporation is a cyclotron technology and radioisotope manufacturing company founded in 2009, spun from accelerator physics developed at the MIT Plasma Science and Fusion Center. Its patented compact superconducting cyclotron, the ION-12SC, was originally built to produce N-13 ammonia (a cardiac PET perfusion tracer) close to the point of care under a pay-per-dose model, and IONETIX has since built a network of such cyclotrons at or near PET programmes, also producing F-18 and Ga-68 diagnostic tracers.\n\nMore recently IONETIX has moved into cyclotron-based alpha-emitter production at a dedicated Alpha Isotope Manufacturing facility in Lansing, Michigan, the first commercial facility built exclusively for alpha-emitting radionuclides. It announced first production of actinium-225 (Ac-225) there in June 2024, describes itself as releasing GMP-grade Ac-225 to customers from late 2024, and began routine shipment of astatine-211 (At-211) in the US in September 2026, produced by irradiating bismuth-209 targets on a 30 MeV cyclotron; it states it is the first non-academic commercial US supplier of At-211. A second Ac-225 cyclotron with dual target stations, intended to allow continuous production scaling to more than 1 curie of Ac-225 per week, began construction in October 2024.\n\nIONETIX raised over $30 million in a 2026 private placement alongside a reverse-merger transaction with JDEV Acquisition Corp that took the company public, with funds earmarked for scaling isotope production and further developing its accelerator technology for medical, materials-testing and nuclear-energy applications. Its supply chain role sits alongside other emerging cyclotron-based alpha-emitter producers, competing on the specific bottleneck of actinium-225 and astatine-211 availability for targeted alpha therapy developers.","status":"active","asOf":"2026-09-22","links":[{"label":"IONETIX: Ionetix Completes $30 million+ Financing in a Go-Public Transaction (2026)","url":"https://ionetix.com/2026/04/21/ionetix-completes-30-million-financing-in-a-go-public-transaction/"},{"label":"IONETIX: about","url":"https://ionetix.com/about/"},{"label":"IONETIX: IONETIX Launches Commercial Actinium-225 Production (2024)","url":"https://ionetix.com/2024/06/07/ionetix-produces-first-batch-of-actinium-225/"},{"label":"IONETIX: Ionetix Begins Shipping Astatine-211 (2026)","url":"https://ionetix.com/2026/09/01/ionetix-begins-shipping-astatine-211-to-support-preclinical-and-clinical-trials/"},{"label":"IONETIX: second cyclotron construction for Ac-225 production (2024)","url":"https://ionetix.com/2024/10/17/ionetix-announces-start-of-construction-to-add-second-cyclotron-for-ac-225-production-at-its-alpha-isotope-manufacturing-facility/"}],"tags":["cyclotron","actinium-225","astatine-211","isotope supply"],"related":["actinium-225-supply","astatine-211-alpha-therapy","cyclotron-isotope-production","targeted-alpha-therapy","f-18","ga-68","n-13","ac-225","at-211"],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Lansing, Michigan, US","country":"US","companyType":"radiopharma","website":"https://ionetix.com","founded":2009,"stage":"public","investors":[],"funding":[]},"route":"/companies/ionetix/","neighbours":{"technology":[{"id":"actinium-225-supply","kind":"technology","name":"Actinium-225 supply: thorium stocks, accelerators and radium targets","route":"/technologies/actinium-225-supply/"},{"id":"astatine-211-alpha-therapy","kind":"technology","name":"Astatine-211 alpha therapy","route":"/technologies/astatine-211-alpha-therapy/"},{"id":"cyclotron-isotope-production","kind":"technology","name":"Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211)","route":"/technologies/cyclotron-isotope-production/"},{"id":"targeted-alpha-therapy","kind":"technology","name":"Targeted alpha therapy","route":"/technologies/targeted-alpha-therapy/"}],"isotope":[{"id":"ac-225","kind":"isotope","name":"Actinium-225","route":"/isotopes/ac-225/"},{"id":"at-211","kind":"isotope","name":"Astatine-211","route":"/isotopes/at-211/"},{"id":"f-18","kind":"isotope","name":"Fluorine-18","route":"/isotopes/f-18/"},{"id":"ga-68","kind":"isotope","name":"Gallium-68","route":"/isotopes/ga-68/"},{"id":"n-13","kind":"isotope","name":"Nitrogen-13","route":"/isotopes/n-13/"}]}}